{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:07:31Z","timestamp":1745467651179,"version":"3.40.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T00:00:00Z","timestamp":1721347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T00:00:00Z","timestamp":1721347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100018935","name":"Universit\u00e4tsklinikum Erlangen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018935","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Carcinoma in situ (CIS) of the bladder is a known parameter regarding the prognosis and recurrence tendency of urothelial carcinomas. Nevertheless, there is little evidence whether the amount of CIS or other precursor lesions, as well as the quantified tumor mass of muscle-invasive urothelial carcinoma, has an influence on the survival or recurrence rate of affected patients. From 80 patients with muscle invasive urothelial bladder cancer and radical cystectomy, 23 samples each were obtained as part of a whole organ mapping in a single institution study, in which the precursor lesions and tumor area were digitally measured and further correlated to pathological standard parameters, patient survival, molecular luminal and basal subtypes, and immune infiltration. Significant correlations were found between tumor mass and surface lining CIS amount for pT-stage, lymphovascular invasion, and perineural infiltration. Furthermore, an increased tumor mass as well as an increased amount of CIS combined with an increased tumor mass showed a significantly reduced survival rate in multivariable analysis (HR\u2009=\u20092.75; <jats:italic>P<\/jats:italic>\u2009=\u20090.019 vs. HR\u2009=\u20093.54; <jats:italic>P<\/jats:italic>\u2009=\u20090.002) as well as a significantly increased recurrence. No correlations could be found with molecular subtypes and immune infiltration. The exact measurement of the tumor mass with and without the CIS surface area, whether manually or, more specifically, digitally, could be incorporated into routine diagnostics and implemented as an independent predictor for patient post-surgical outcomes. It can therefore serve as an additional predictor for risk stratification and, if necessary, intensified follow-up care or therapy.<\/jats:p>","DOI":"10.1007\/s00428-024-03875-9","type":"journal-article","created":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T14:02:34Z","timestamp":1721397754000},"page":"769-779","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Digital volumetric assessment of CIS and tumor mass compliments conventional histopathological assessment in muscle-invasive urothelial bladder cancer"],"prefix":"10.1007","volume":"486","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2707-7676","authenticated-orcid":false,"given":"Fabienne","family":"Lange","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol I.","family":"Geppert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronika","family":"Bahlinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Bertz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"St\u00f6hr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danijel","family":"Sikic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helge","family":"Taubert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sven","family":"Wach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd","family":"Wullich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arndt","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Eckstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,19]]},"reference":[{"key":"3875_CR1","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.eururo.2015.10.024","volume":"69","author":"J Leal","year":"2016","unstructured":"Leal J, Luengo-Fernandez R, Sullivan R, Witjes JA (2016) Economic burden of bladder cancer across the European Union. Eur Urol 69:438\u2013447","journal-title":"Eur Urol"},{"key":"3875_CR2","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.eururo.2016.06.010","volume":"71","author":"S Antoni","year":"2017","unstructured":"Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F (2017) Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol 71:96\u2013108","journal-title":"Eur Urol"},{"key":"3875_CR3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/00005392-200101000-00012","volume":"165","author":"A Vaidya","year":"2001","unstructured":"Vaidya A, Soloway MS, Hawke C, Tiguert R, Civantos F (2001) De novo muscle invasive bladder cancer: is there a change in trend? J Urol 165:47\u201350 (discussion 50)","journal-title":"J Urol"},{"key":"3875_CR4","doi-asserted-by":"publisher","first-page":"446","DOI":"10.6004\/jnccn.2013.0059","volume":"11","author":"PE Clark","year":"2013","unstructured":"Clark PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW et al (2013) Bladder cancer. J Natl Compr Cancer Netw JNCCN 11:446\u2013475","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"key":"3875_CR5","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD et al (2017) Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 171:540-556.e25","journal-title":"Cell"},{"key":"3875_CR6","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s00428-018-2354-9","volume":"472","author":"I Barth","year":"2018","unstructured":"Barth I, Schneider U, Grimm T, Karl A, Horst D, Gaisa NT et al (2018) Progression of urothelial carcinoma in situ of the urinary bladder: a switch from luminal to basal phenotype and related therapeutic implications. Virchows Arch 472:749\u2013758","journal-title":"Virchows Arch"},{"key":"3875_CR7","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","volume":"25","author":"W Choi","year":"2014","unstructured":"Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J et al (2014) Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25:152\u2013165","journal-title":"Cancer Cell"},{"key":"3875_CR8","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.eururo.2017.03.030","volume":"72","author":"R Seiler","year":"2017","unstructured":"Seiler R, Ashab HAD, Erho N, van Rhijn BWG, Winters B, Douglas J et al (2017) Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy. Eur Urol 72:544\u2013554","journal-title":"Eur Urol"},{"key":"3875_CR9","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.urology.2005.07.062","volume":"66","author":"Z Kirkali","year":"2005","unstructured":"Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L et al (2005) Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 66:4\u201334","journal-title":"Urology"},{"key":"3875_CR10","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.critrevonc.2010.01.005","volume":"76","author":"SR Williamson","year":"2010","unstructured":"Williamson SR, Montironi R, Lopez-Beltran A, MacLennan GT, Davidson DD, Cheng L (2010) Diagnosis, evaluation and treatment of carcinoma in situ of the urinary bladder: the state of the art. Crit Rev Oncol Hematol 76:112\u2013126","journal-title":"Crit Rev Oncol Hematol"},{"key":"3875_CR11","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk M, Burger M, Capoun O, Cohen D, Comp\u00e9rat EM, Dominguez Escrig JL et al (2022) European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol 81:75\u201394","journal-title":"Eur Urol"},{"key":"3875_CR12","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.eururo.2014.10.040","volume":"67","author":"RG Casey","year":"2015","unstructured":"Casey RG, Catto JWF, Cheng L, Cookson MS, Herr H, Shariat S et al (2015) Diagnosis and management of urothelial carcinoma in situ of the lower urinary tract: a systematic review. Eur Urol 67:876\u2013888","journal-title":"Eur Urol"},{"key":"3875_CR13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1471-2490-11-17","volume":"11","author":"M Miyake","year":"2011","unstructured":"Miyake M, Hirao S, Mibu H, Tanaka M, Takashima K, Shimada K et al (2011) Clinical significance of subepithelial growth patterns in non-muscle invasive bladder cancer. BMC Urol 11:17","journal-title":"BMC Urol"},{"key":"3875_CR14","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.juro.2018.05.162","volume":"201","author":"S Kimura","year":"2019","unstructured":"Kimura S, Mari A, Foerster B, Abufaraj M, Vartolomei MD, Stangl-Kremser J et al (2019) Prognostic value of concomitant carcinoma in situ in the radical cystectomy specimen: a systematic review and meta-analysis. J Urol 201:46\u201353","journal-title":"J Urol"},{"key":"3875_CR15","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1159\/000325463","volume":"87","author":"P Nuhn","year":"2011","unstructured":"Nuhn P, Bastian PJ, Novara G, Svatek RS, Karakiewicz PI, Skinner E et al (2011) Concomitant carcinoma in situ in cystectomy specimens is not associated with clinical outcomes after surgery. Urol Int 87:42\u201348","journal-title":"Urol Int"},{"key":"3875_CR16","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1007\/s00345-013-1207-z","volume":"32","author":"FA Yafi","year":"2014","unstructured":"Yafi FA, Aprikian AG, Chin JL, Fradet Y, Izawa J, Estey E et al (2014) Impact of concomitant carcinoma in situ on upstaging and outcome following radical cystectomy for bladder cancer. World J Urol 32:1295\u20131301","journal-title":"World J Urol"},{"key":"3875_CR17","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.eururo.2006.08.037","volume":"51","author":"SF Shariat","year":"2007","unstructured":"Shariat SF, Palapattu GS, Karakiewicz PI, Rogers CG, Vazina A, Bastian PJ et al (2007) Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomy. Eur Urol 51:152\u2013160","journal-title":"Eur Urol"},{"key":"3875_CR18","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1158\/0008-5472.CAN-20-2336","volume":"81","author":"A Wullweber","year":"2021","unstructured":"Wullweber A, Strick R, Lange F, Sikic D, Taubert H, Wach S et al (2021) Bladder tumor subtype commitment occurs in carcinoma in situ driven by key signaling pathways including ECM remodeling. Can Res 81:1552\u20131566","journal-title":"Can Res"},{"key":"3875_CR19","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3390\/genes12020230","volume":"12","author":"V Weyerer","year":"2021","unstructured":"Weyerer V, Eckstein M, Strissel PL, Wullweber A, Lange F, T\u00f6gel L et al (2021) TERT promoter mutation analysis of whole-organ mapping bladder cancers. Genes 12:230","journal-title":"Genes"},{"key":"3875_CR20","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1158\/2326-6066.CIR-18-0758","volume":"7","author":"C Pfannstiel","year":"2019","unstructured":"Pfannstiel C, Strissel PL, Chiappinelli KB, Sikic D, Wach S, Wirtz RM et al (2019) The tumor immune microenvironment drives a prognostic relevance that correlates with bladder cancer subtypes. Cancer Immunol Res 7:923\u2013938","journal-title":"Cancer Immunol Res"},{"key":"3875_CR21","doi-asserted-by":"publisher","first-page":"e000162","DOI":"10.1136\/jitc-2019-000162","volume":"8","author":"M Eckstein","year":"2020","unstructured":"Eckstein M, Strissel P, Strick R, Weyerer V, Wirtz R, Pfannstiel C et al (2020) Cytotoxic T-cell-related gene expression signature predicts improved survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and adjuvant chemotherapy. J Immunother Cancer 8:e000162","journal-title":"J Immunother Cancer"},{"key":"3875_CR22","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.eururo.2016.02.028","volume":"70","author":"PA Humphrey","year":"2016","unstructured":"Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE (2016) The 2016 WHO classification of tumours of the urinary system and male genital organs-part b: prostate and bladder tumours. Eur Urol 70:106\u2013119","journal-title":"Eur Urol"},{"key":"3875_CR23","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/PAP.0000000000000308","volume":"28","author":"MB Amin","year":"2021","unstructured":"Amin MB, Comperat E, Epstein JI, True LD, Hansel D, Paner GP et al (2021) The genitourinary pathology society update on classification and grading of flat and papillary urothelial neoplasia with new reporting recommendations and approach to lesions with mixed and early patterns of neoplasia. Adv Anat Pathol 28:179\u2013195","journal-title":"Adv Anat Pathol"},{"key":"#cr-split#-3875_CR24.1","unstructured":"R: the R project for statistical computing [Internet] [updated 2022 Apr 22"},{"key":"#cr-split#-3875_CR24.2","unstructured":"cited 2022 Jun 6]. Available from: https:\/\/www.r-project.org\/."},{"key":"3875_CR25","doi-asserted-by":"publisher","first-page":"4040","DOI":"10.1158\/0008-5472.CAN-03-3620","volume":"64","author":"L Dyrskj\u00f8t","year":"2004","unstructured":"Dyrskj\u00f8t L, Kruh\u00f8ffer M, Thykjaer T, Marcussen N, Jensen JL, M\u00f8ller K et al (2004) Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Can Res 64:4040\u20134048","journal-title":"Can Res"},{"key":"3875_CR26","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0002-9440(10)65318-7","volume":"154","author":"A Hartmann","year":"1999","unstructured":"Hartmann A, Moser K, Kriegmair M, Hofstetter A, Hofstaedter F, Knuechel R (1999) Frequent genetic alterations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma. Am J Pathol 154:721\u2013727","journal-title":"Am J Pathol"},{"key":"3875_CR27","first-page":"809","volume":"62","author":"A Hartmann","year":"2002","unstructured":"Hartmann A, Schlake G, Zaak D, Hungerhuber E, Hofstetter A, Hofstaedter F et al (2002) Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder. Can Res 62:809\u2013818","journal-title":"Can Res"},{"key":"3875_CR28","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/path.1175","volume":"198","author":"C Steidl","year":"2002","unstructured":"Steidl C, Simon R, B\u00fcrger H, Brinkschmidt C, Hertle L, B\u00f6cker W et al (2002) Patterns of chromosomal aberrations in urinary bladder tumours and adjacent urothelium. J Pathol 198:115\u2013120","journal-title":"J Pathol"},{"key":"3875_CR29","doi-asserted-by":"publisher","first-page":"4011","DOI":"10.1007\/s00345-021-03788-1","volume":"39","author":"V Weyerer","year":"2021","unstructured":"Weyerer V, Stoehr R, Bertz S, Lange F, Geppert CI, Wach S et al (2021) Prognostic impact of molecular muscle-invasive bladder cancer subtyping approaches and correlations with variant histology in a population-based mono-institutional cystectomy cohort. World J Urol 39:4011\u20134019","journal-title":"World J Urol"},{"key":"3875_CR30","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1111\/bju.14108","volume":"121","author":"ON Gofrit","year":"2018","unstructured":"Gofrit ON, Pode D, Pizov G, Duvdevani M, Landau EH, Hidas G et al (2018) \u2018Very-low-risk\u2019 bladder tumours - a new entity? BJU Int 121:627\u2013631","journal-title":"BJU Int"},{"key":"3875_CR31","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/iju.13913","volume":"26","author":"A Lee","year":"2019","unstructured":"Lee A, Lee HJ, Huang HH, Ho H, Chen K (2019) Low-risk non-muscle-invasive bladder cancer: further prognostic stratification into the \u201cvery-low-risk\u201d group based on tumor size. Int J Urol 26:481\u2013486","journal-title":"Int J Urol"},{"key":"3875_CR32","doi-asserted-by":"publisher","first-page":"3967","DOI":"10.1200\/JCO.2005.05.3884","volume":"24","author":"BH Bochner","year":"2006","unstructured":"Bochner BH, Kattan MW, Vora KC (2006) Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol 24:3967\u20133972","journal-title":"J Clin Oncol"},{"key":"3875_CR33","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","volume":"77","author":"A Kamoun","year":"2020","unstructured":"Kamoun A, de Reyni\u00e8s A, Allory Y, Sj\u00f6dahl G, Robertson AG, Seiler R et al (2020) A consensus molecular classification of muscle-invasive bladder cancer. Eur Urol 77:420\u2013433","journal-title":"Eur Urol"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-024-03875-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-024-03875-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-024-03875-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T06:18:17Z","timestamp":1745389097000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-024-03875-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,19]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["3875"],"URL":"https:\/\/doi.org\/10.1007\/s00428-024-03875-9","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"type":"print","value":"0945-6317"},{"type":"electronic","value":"1432-2307"}],"subject":[],"published":{"date-parts":[[2024,7,19]]},"assertion":[{"value":"7 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"FL reports no conflict of interest.CG reports speaker\u2019s honoraria from Sysmex.VB reports speaker\u2019s honoraria from MSD and Biocartis and reports research funding from Gilead.SB reports no conflict of interest.RS reports no conflict of interest.DS reports no conflict of interest.HT reports speaker honoraria from Qiagen.SW reports no conflict of interest.BW reports speaker\u2019s honoraria from Astellas, Janssen-Cilag, and MSD.AH reports honoraria for lectures for Eisai, Abbvie, AstraZeneca, Biontech, BMS, Boehringer Ingelheim, Cepheid, Diaceutics, Ipsen, Janssen, Lilly, MSD, Nanostring, Novartis, Roche, and 3DHistotech; advisory role for Abbvie, AstraZeneca, Biontech, BMS, Boehringer Ingelheim, Cepheid, Diaceutics, Gilead, Illumina, Ipsen, Janssen, Lilly, MSD, Nanostring, Novartis, Qiagen, QUIP GmbH, Roche, and 3DHistotech; and research funding from AstraZeneca, Biontech, Cepheid, Gilead, Illumina, Janssen, Nanostring, Qiagen, QUIP GmbH, Roche, STRATIFYER, and Owkin.ME reports speaker\u2019s honoraria from Eisai, Roche, Astellas, MSD, AstraZeneca, Janssen-Cilag, Cepheid, and Diaceutics; reports research funding from STRATIFYER, AstraZeneca, Janssen-Cilag, Gilead Sciences, Cepheid, and Owkin; reports advisory honoraria from AstraZeneca, Janssen-Cilag, GenomicHealth, Cepheid, and Diaceutics; and reports a part time employment as scientific advisor for Diaceutics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}